BCLI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Brainstorm Cell Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Business Wire • 11/20/23
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA to Discuss Confirmatory Phase 3 Trial for NurOwn® in ALSPRNewsWire • 11/20/23
BRAINSTORM SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their OptionsPRNewsWire • 11/18/23
ROSEN, A LEADING LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 11/16/23
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)Business Wire • 11/14/23
BrainStorm Cell Therapeutics Announces Third quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 11/14/23
Brainstorm Cell Therapeutics Inc. (BCLI) Investors: Shareholders with Large Losses Should Contact Robbins LLP Regarding the BCLI Class ActionBusiness Wire • 11/14/23
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. (BCLI)Business Wire • 11/13/23
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 11/08/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) InvestorsBusiness Wire • 11/08/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) InvestorsBusiness Wire • 11/07/23
BrainStorm to Announce Third Quarter 2023 Financial Results and Provide a Corporate UpdatePRNewsWire • 11/07/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Brainstorm Cell Therapeutics Inc. with Losses of $100,000 to Contact the FirmAccesswire • 11/07/23
Brainstorm Cell Therapeutics Inc. (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Brainstorm Cell Therapeutics Inc.Business Wire • 11/06/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of InvestorsBusiness Wire • 11/06/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of InvestorsBusiness Wire • 11/06/23
BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the FirmBusiness Wire • 11/04/23
The Law Offices of Frank R. Cruz Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of InvestorsBusiness Wire • 11/03/23
BRAINSTORM SHAREHOLDER ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Brainstorm To Contact Him Directly To Discuss Their OptionsPRNewsWire • 11/03/23
NATIONALLY RANKED ROSEN LAW FIRM Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCLIPRNewsWire • 11/03/23
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. – BCLIBusiness Wire • 11/01/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Brainstorm Cell Therapeutics Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 10/30/23
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn® for the Treatment of ALSPRNewsWire • 10/24/23
